Takeda’s real estate downsize will add to the region’s growing office sublease market. A January 2026 CBRE report on the ...

The pharmaceutical company said Thursday that about 47% of patients between the ages of two and 17 reached the primary endpoint of clinical remission after 54 weeks. About 35% reached clinical ...

Takeda Shingen is the main villain of the 1572 CE era in Nioh 3. After facing him in the Crucible during The Battle of ...

The partnership aims to advance high-priority small molecule programmes using Iambic’s AI models and wet lab capabilities.

NEW YORK, NY, UNITED STATES, January 28, 2026 /EINPresswire.com/ -- Hexagon Health is proud to congratulate Brian ...

How to beat Takeda Shingen (Yokai version) in Nioh 3.

Takeda Shingen is a pivotal foe fought several times in Nioh 3. Here's how to beat him in each encounter.

After sharing word that it would be prioritizing artificial intelligence to aid discovery work, Takeda Pharmaceuticals has inked a multiyear deal to access Iambic Therapeutics' broad suite of& | ...

Iambic and Takeda Pharmaceutical have formed a multi-year partnership valued at over $1.7 billion. This collaboration will ...

Iambic’s physics-informed NeuralPLexer is intended to enhance protein–ligand modeling, enabling broader exploration of ...

FDA Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton as a Potential First-in-Class Therapy ...

Takeda Pharmaceutical will apply Iambic Therapeutics’ artificial intelligence (AI)-based technologies and wet lab capabilities to design and develop small molecule drugs through a multi-year tech and ...